Ani Pharmaceuticals, Inc revenue by segment ANIP

Annual Quarterly

Ani Pharmaceuticals, Inc splits its revenue into 12 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Sales Of Generic Pharmaceutical Products at $384.1 million, 43% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	1,041	883	614	487	316	216	208	207	202	177	129
Sales Of Generic Pharmaceutical Products	410 +13.2% share 39.3%	384 +27.6% share 43.5%	301 +11.7% share 49.0%	269 +28.2% share 55.3%	210 +46.4% share 66.4%	144 -2.5% share 66.4%	147 +14.4% share 70.6%	129 share 62.3%	—	—	—
Sales Of Cortrophin Gel	442 +49.6% share 42.5%	348 +75.6% share 39.4%	198 +76.7% share 32.2%	112 +169.0% share 23.0%	42 share 13.2%	—	—	—	—	—	—
Total Sales Of Rare Disease Pharmaceutical Products	—	—	—	112 +169.0% share 23.0%	42 share 13.2%	—	—	—	—	—	—
Sales Of ILUVIEN And YUTIQ	80 -3.1% share 7.7%	75 +137.6% share 8.5%	32 share 5.1%	—	—	—	—	—	—	—	—
Sales Of Branded Pharmaceutical Products	—	—	—	—	65 -11.0% share 20.4%	73 +51.3% share 33.6%	48 -24.8% share 23.0%	64 share 30.9%	—	—	—
Sales Of Established Brands	46 -32.5% share 4.5%	61 -5.3% share 6.9%	65 -24.2% share 10.5%	85 share 17.5%	—	—	—	—	—	—	—
Unapproved Products	24 +3.8% share 2.4%	24 +7.6% share 2.7%	22 +0.0% share 3.6%	22 +57.7% share 4.6%	14 -12.3% share 4.5%	16 -4.1% share 7.5%	17 -18.4% share 8.1%	21 share 10.0%	—	—	—
Sales Of Generic Other Revenues	12 -31.5% share 1.2%	15 -19.6% share 1.7%	19 -4.2% share 3.1%	20 -20.9% share 4.1%	25 share 7.9%	—	—	—	—	—	—
Sales Of Contract Manufactured Products	—	—	—	—	—	10 +8.9% share 4.6%	9 -17.2% share 4.4%	11 share 5.4%	—	—	—
Other Revenues	—	—	—	—	—	2 +137.2% share 0.9%	1 -20.1% share 0.4%	1 share 0.5%	—	—	—
Royalties From Licensing Agreements	—	—	—	—	—	—	1 +73.0% share 0.7%	1 share 0.4%	—	—	—
Product Development Services	—	—	—	—	—	1 share 0.6%	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ANIP (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Princeton, NJ
SEC filer status: Large accelerated filer
SEC CIK: 1023024
Former names: BIOSANTE PHARMACEUTICALS INC (until Jul 18, 2013); BEN ABRAHAM TECHNOLOGIES INC (until Dec 23, 1999)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.